Indication
Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.
Loading your page…
Loading your page…
Obesity
Marketing Authorisation Holder: Haleon Ireland Dungarvan Limited
EMA Authorisation: 22/07/2007
INN: orlistat
AI Drug & Interaction Analysis
Free account required
Ask Osler about Alli (previously Orlistat GSK): drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.